Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors

Current Opinion in Pharmacology

Volumn 6, Issue 2, 2006, Pages 162-168

  Clark, Ronald W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ABC TRANSPORTER A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NEW DRUG; PLACEBO; PRAVASTATIN; SCAVENGER RECEPTOR BI; TORCETRAPIB; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CATALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HUMAN; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW;

ATHEROSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS; FEMALE; GLYCOPROTEINS; HUMANS; LIPOPROTEINS, HDL; MALE; QUINOLINES; SULFHYDRYL COMPOUNDS;

EID: 33644839176     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.10.012     Document Type: Review

References (57)

1. Heart Protection Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomized placebo-controlled trial Lancet 360 2002 7-22
2. J. Shepherd G.J. Blauw M.B. Murphy E.L. Bollen B.M. Buckley S.M. Cobbe I. Ford I. Gaw M. Hyland J.W. Jujema et. al. PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial Lancet 360 2002 1623-1630
3. P.S. Sever B. Dahlof N.R. Poulter H. Wedel G. Beevers M. Caulfield R. Colins S.E. Kjeldsen A. Kristinsson G.T. McInnes et. al. Prevention of coronary and stroke events with the atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial Lancet 361 2003 1149-1158
4. C.P. Cannon E. Braunwald C.H. McCabe D.J. Rader J.L. Rouleau R. Belder S.V. Joval K.A. Hill M.A. Pfeffer A.M. Skene Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495-1504
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
6. A. Goldberg P. Alagona D.M. Capuzzi J. Guyton J.M. Morgan J. Rodgers R. Sachson P. Samuel Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia Am J Cardiol 85 2000 1100-1105
7. J.R. Guyton M.A. Blazing J. Hagar M.L. Kashyap R.H. Knopp J.M. McKenny D.T. Nash Nash SD for the Niaspan-Gemfibrozil Study Group Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol Arch Intern Med 160 2000 1177-1184
8. B.G. Brown X. Zhao A. Chait L.D. Fisher M.C. Cheung J.S. Morse A.A. Dowdy E.K. Marino E.L. Bolson P. Alaupovic et. al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583-1592
9. J. McKenney New perspectives on the use of niacin in the treatment of lipid disorders Arch Intern Med 164 2004 697-705
10. A. Inazu M.L. Brown C.B. Hesler L.B. Agellon J. Koizumi K. Takata Y. Maruhama H. Mabuchi A.R. Tall Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation N Engl J Med 323 1990 1234-1238
11. R.W. Clark G. Chang M.T. Didiuk Agents for the inhibition of cholesteryl ester transfer protein (CETP) and prospects for the future treatment of atherosclerosis Curr Med Chem - Immunol Endocr & Metab Agents 5 2005 339-360
12. G.J. de Grooth J.A. Kuivenhoven A.F.H. Stalenhoef J. de Graaf A.H. Zwinderman J.L. Posma A. van Tol J.J.P. Kastelein Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans Circulation 105 2002 2159-2165
13. J.A. Kuivenhoven G.J. Grooth H. Kawamura A.H. Klerkx F. Wilhelm M.D. Trip J.J.P. Kastelein Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia Am J Cardiol 95 2005 1085-1088
14. R.J. Bisoendial G.K. Hovingh K.L. Harchaoui J.H.M. Levels S. Tsimikas K. Pu A.E. Zwinderman J.A. Kuivenhoven J.J.P. Kastelein E.S.G. Stroes Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia Arterioscler Thromb Vasc Biol 25 2005 e133-e134
15. R.W. Clark T.A. Sutfin R.B. Ruggeri A.T. Willauer E.D. Sugarman G. Magnus-Aryitey P.G. Cosgrove T.M. Sand R.T. Wester J.A. Williams et. al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib Arterioscler Thromb Vasc Biol 24 2004 490-497
16. M.E. Brousseau E.J. Schaefer B.S. Wolfe L.T. Bloedon A.G. Digenio R.W. Clark J.P. Mancuso D.J. Rader Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505-1515
17. Davidson M, McKenney J, Revkin JH, Shear CL: Efficacy and safety of a novel CETP inhibitor torcetrapib administered with and without atorvastatin in subjects with a low level of HDL-C. Am Coll Cardiol Annual Scientific Session 2005. 6-9 March 2005. Orlando, FL, USA [Presentation # 802-3].
18. R.W. Clark R.B. Ruggeri D. Cunningham M.J. Bamberger Description of the torcetrapib series of cholesteryl transfer protein inhibitors, including mechanism of action J Lipid Res 47 2006 537-552
19. G.R. Castro C.J. Fielding Early incorporation of cell-derived cholesterol into preβ-migrating high density lipoprotein Biochemistry 27 1988 25-29
20. O.L. Francone A. Gurakar C.J. Fielding Distribution and functions of lecithin: cholesterol acyl-transferase and cholesteryl ester transfer protein in plasma lipoproteins J Biol Chem 264 1989 7066-7072
21. T. Ohta R. Nakamura K. Takata Y. Saito S. Yamashita S. Horiuchi I.J. Matsuda Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency J Lipid Res 36 1995 696-704
22. M. Ishigami S. Yamashita N. Sakai T. Arai K. Hirano H. Hiraoka K. Kameda-Takemura Y.J. Matsuzawa Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages fromcholesterol accumulation induced by acetylated low-density lipoproteins Biochem 116 1994 257-262
23. S. Zhong D.S. Sharp J.S. Grove C. Bruce K. Yano J.D. Curb A.R. Tall Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels J Clin Invest 97 1996 2917-2923
24. Y. Moriyama T. Okamura A. Inazu M. Doi H. Iso Y. Mouri Y. Ishikawa H. Suzuki M. Iida J. Koizumi et. al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesteryl levels, including those with plasma cholesteryl ester transfer protein deficiency Prev Med 27 1998 659-667
25. J.D. Curb R.D. Abbott B.L. Rodriguez K. Masaki R. Chen D.S. Sharp A.R. Tall A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly J Lipid Res 45 2004 948-953
26. S.M. Boekholdt J.-A. Kuivenhoven N.J. Wareham R.J.G. Peters J.W. Jukema R. Luben S.A. Bingham N.E. Day J.J.P. Kastelein K.-T. Khaw Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women Circulation 110 2004 1418-1423
27. A.H.E.M. Klerkx G.J. de Grooth A.H. Zwinderman J.W. Jukema J.A. Kuivenhoven J.J.P. Kastelein Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS) Eur J Clin Invest 34 2004 21-28
28. H.B. Brewer A.T. Remaley E.B. Neufeld F. Basso C. Joyce Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease Arterioscler Thromb Vasc Biol 24 2004 1755-1760
29. N. Wang D. Lan W. Chen F. Matsuura A.R. Tall ATP-binding cassette transporters G1 and G4 mediate cellular efflux to high density lipoproteins Proc Natl Acad Sci USA 101 2004 9774-9779
30. M.A. Kennedy G.C. Barrera K. Nakamura A. Baldan P. Tarr M.C. Fishbein J. Frank O.L. Francone P.A. Edwards ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation Cell Metab 1 2005 121-131
31. M.A. Connelly D.L. Williams Scavenger receptor BI: A scavenger receptor with a mission to transport high density lipoprotein lipids Curr Opin Lipidol 15 2004 287-295
32. M.E. Brousseau M.R. Diffenderfer J.S. Millar C. Nortsupha B.F. Asztalos F.K. Welty M.L. Wolfe M. Rudling I. Bjorkhem B. Angelin et. al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion Arterioscler Thromb Vasc Biol 25 2005 1057-1064
33. M. Haghpassand Bourassa P-AK O.L. Francone R.J. Aiello Monocyte/ macrophage expression of ABCA1 has minimal contribution to plasma HDL levels J Clin Invest 108 2001 1315-1320
34. Wang N, Lan D, Chen W, Matsuura F, Tall AR: ATP-binding cassette transporters mediate cellular efflux to high density lipoproteins. Keystone Symposia 2005: The Cellular Biology of Atherosclerosis, 22-27 January 2005. Keystone, CO, USA [Abstract # 034].
35. C.C. Schwartz J.M. VanderBroek P.S. Cooper Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans J Lipid Res 45 2004 1594-1607
36. L. Dory C.H. Sloop L.M. Boquet R.L. Hamilton P.S. Roheim Lecithin: cholesterol acyltransferase-mediated modification of discoidal peripheral lymph high density lipoproteins: Possible mechanism of formation of cholesterol-induced high density lipoproteins (HDLc) in cholesterol-fed dogs Proc Natl Acad Sci USA 80 1983 3489-3493
37. M.N. Nanjee C.J. Cooke W.J. Olszewski N.E. Miller Concentratons of electrophoretic and size subclasses of apolipoprotein A-I-containing particles in human peripheral lymph Arterioscler Thromb Vasc Biol 20 2000 2148-2155
38. J.W. Burgess J. Boucher T.A. Neville P. Rouillard C. Stamler S. Zachariah D. Sparks Phosphatidylinositol promotes cholesterol transport and excretion J Lipid Res 44 2003 1355-1363
39. J.W. Burgess T.A. Neville P. Rouillard Z. Harder D.S. Beanlands D.L. Sparks Phosphatidylinositol increases HDL-C levels in humans J Lipid Res 46 2005 350-355
40. P.J. Barter G.J. Hopkins L. Gorjatschko M.E. Jones Competitive inhibition of plasma esterification by human high density lipoprotein-subfraction 2 Biochim Biophys Acta 793 1984 260-268
41. B. Zhang P. Fan E. Shimoji H. Xu K. Takeuchi C. Bian K. Saku Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits Arterioscler Thromb Vasc Biol 24 2004 1910-1915
42. M. Dobiasova Atherogenic index of plasma [log(triglycerides/ HDL-cholesterol)]:tHeoretical and practical implications Clin Chem 50 2004 1113-1115
43. S.J. Robins J.M. Fasulo Delineation of a novel hepatic route for the selective transfer of unesterified sterols from high-density lipoproteins to bile: Studies using the perfused rat liver Hepatology 29 1999 1541-1548
44. M.W. Scobey F.L. Johnson L.L. Rudel Delivery of high-density lipoprotein free and esterified cholesterol to bile by the perfused monkey liver Am J Physiol 257 1989 G644-G652
45. D. Wustner M. Mondal A. Huang F.R. Maxfield Different transport routes for high density lipoprotein and its associated free sterol in polarized hepatic cells J Lipid Res 45 2004 427-437
46. D. Wustner Mathematical analysis of hepatic high density lipoprotein transport based on quantitative imaging data J Biol Chem 280 2005 6766-6779
47. K. Ikewaki M. Nishiwaki T. Sakamoto T. Ishikawa T. Fairwell L.A. Zech M. Nagano H. Nakamura H.B. Brewer D.J. Rader Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency J Clin Invest 96 1995 1573-1581
48. Millar JS, Brousseau ME, Diffenderfer MR, Barrett HR, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP et al.: Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler Thromb Vasc Biol 2006, in press.
49. B.F. Asztalos M. Batista K.V. Horvath C.E. Cox G.E. Dallal J.S. Morse G.B. Brown E.J. Schaefer Change in α-1 HDL concentration predicts progression in coronary artery stenosis Arterioscler Thromb Vasc Biol 23 2003 847-852
50. P.T. Williams R. Superko W.L. Haskell E.L. Alderman P.J. Blanche L.G. Glines R.M. Krauss Smallest LDL particles are most strongly related to coronary disease progression in men Arterioscler Thromb Vasc Biol 23 2003 314-321
51. N. Duverger D. Rader K. Ikiwaki T. Nishiwaki T. Sakamoto T. Ishikawa M. Nagano H. Nakamura H.B. Brewer Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency Eur J Biochem 227 1995 123-129
52. H. Chiba H. Akita K. Tsuchihashi S. Hui Y. Takahashi H. Fuda H. Suzuki H. Shibuya M. Tsuji K. Kobayashi Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency J Lipid Res 38 1997 1204-1216
53. J. Koizumi I. Inazu K. Yagi I. Koizumi Y. Uno K. Kajinami S. Miyamoto P. Moulin A.R. Tall H. Mabuchi Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency Atherosclerosis 90 1991 189-196
54. S. Yamashita D.L. Sprecher N. Sakai Y. Matsuzawa S. Tarui D.Y. Hui Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency J Clin Invest 86 1990 688-695
55. H. Okamoto Y. Iwamoto M. Maki T. Sotani F. Yonemori K. Wakitani Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals Eur J Pharmacol 466 2003 147-154
56. Milano infusion in healthy volunteers Clin Chem 48 2002 680-681
57. Bamberger MJ, Moya M, Durham K, Shear CL, Nguyen TT, Revkin JH, Rothblat G: CETP inhibition in humans maintains the cholesterol efflux potential of HDL. The American Heart Association Scientific Sessions 2005. November 2005. Dallas, TX, USA [Abstract 941].